12 unknown, 6 completed, 1 not yet recruiting, 1 recruiting. 8 Phase 2, 4 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 7, Completed 1 |
| Phase 3 | 4 | Unknown 4 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow EGFR-TKI: new trials by email Literature Review of EGFR-TKI trials Research Report on EGFR-TKI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients EGFR-TKI - Non Small Cell Lung Cancer NSCLC | Not yet recruiting | Guangzhou University of Traditional Chinese Medicine | 3000 | 2026-01-01 | 2026-01-13 | |
| Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer EGFR-TKI, EGFR tyrosine kinase inhibitor - Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term) | Completed | Taichung Veterans General Hospital | 100 | 2022-06-01 | 2025-12-05 | |
| Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 50 | 2021-08-01 | 2022-08-19 |
| Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer Nimotuzumab - Leptomeningeal Metastasis, Lung Cancer | Phase 2 | Unknown | Hui Bu | 30 | 2021-04-19 | 2021-04-20 |
| Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients EGFR-TKI, EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin) - Non-small-lung-cell Cancer, NSCLC | Not applicable | Completed | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 114 | 2020-11-23 | 2024-01-16 |
| Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC Third-generation EGFR-TKI, EGFR-TKI - Non-small Cell Lung Cancer | Recruiting | Hunan Province Tumor Hospital | 800 | 2020-03-24 | 2025-01-27 | |
| Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma Thoracic radiotherapy, EGFR-TKI - Lung Cancer Stage III, EGFR Activating Mutation | Completed | Laibin People's Hospital | 202 | 2020-01-01 | 2026-10-05 | |
| First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer FHND-9041 - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Completed | Yongchang Zhang | 124 | 2019-06-27 | 2024-07-25 |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC Apatinib, EGFR-TKI - Lung Diseases, Neoplasms | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 144 | 2018-12-30 | 2018-01-03 |
| A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation FCN-411 Dose-escalation, FCN-411 Dose-expansion - Lung Cancer | Phase 1 / Phase 2 | Unknown | Ahon Pharmaceutical Co., Ltd. | 90 | 2018-08-01 | 2020-07-16 |
| EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism EGFR-TK Inhibitor, EGFR-TKI, EGFR-TKI and Chemotherapy - Nonsmall Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 50 | 2016-12-01 | 2016-12-28 |
| EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism EGFR-TKI, Chemotherapy（pemetrexed/gemcitabine）, Chemotherapy（carboplatin） - Non-Small-Cell Lung Cancer | Phase 3 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2016-08-01 | 2016-08-09 |
| A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy EGFR-TKI, Thoracic Hypofractionated Radiotherapy - Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | First People's Hospital of Hangzhou | 76 | 2016-05-01 | 2016-06-02 |
| Cryotherapy Combine Icotinib for Advanced NSCLC Treatment Cryotherapy, Icotinib - Lung Neoplasms | Phase 4 | Completed | Fuda Cancer Hospital, Guangzhou | 60 | 2016-04-01 | 2020-05-27 |
| EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC EGFR-TKI, whole brain radiotherapy - Non-Small Cell Lung Cancer | Phase 3 | Unknown | Sun Yat-sen University | 601 | 2015-08-01 | 2017-10-27 |
| Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib, WBRT, HFSRS - Stage IV EGFR Mutated NSCL With Brain Metastases | Phase 3 | Unknown | Sichuan Provincial People's Hospital | 325 | 2015-03-01 | 2016-08-30 |
| Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC EGFR-TKI - Asymptomatic Brain Metastases of Non Small Cell Lung Cancer | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 70 | 2015-01-01 | 2014-09-26 |
| Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1 EGFR-TKI, PD-1/PD-L1 inhibitor, EGFR-TKI combined with PD-1/PD-L1 - Non-Small Cell Lung Cancer (NSCLC) | Completed | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 67818 | 2015-01-01 | 2025-06-25 | |
| Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma TCM, EGFR-TKI - Cancer | Unknown | Shanghai University of Traditional Chinese Medicine | 470 | 2011-11-01 | 2016-07-13 | |
| Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001) Prophylactic cranial irradiation, Erlotinib /Gefitinib - Non-small Cell Lung Cancer | Phase 3 | Unknown | Zhejiang Cancer Hospital | 200 | 2010-06-01 | 2010-07-08 |
Carcinoma, Non-Small-Cell Lung (11) · Lung Neoplasms (5) · Brain Neoplasms (2) · Neoplasms (2) · Adenocarcinoma of Lung (1) · Cardiotoxicity (1) · Lung Diseases (1) · Meningeal Carcinomatosis (1) · Respiratory Tract Diseases (1) · Thoracic Neoplasms (1)
Shanghai Pulmonary Hospital, Shanghai, China (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Ahon Pharmaceutical Co., Ltd. (1) · First People's Hospital of Hangzhou (1) · Fuda Cancer Hospital, Guangzhou (1) · Guangzhou University of Traditional Chinese Medicine (1) · Hui Bu (1) · Hunan Province Tumor Hospital (1) · Laibin People's Hospital (1) · Shanghai University of Traditional Chinese Medicine (1) · Sichuan Cancer Hospital and Research Institute (1) · Sichuan Provincial People's Hospital (1) · Sun Yat-sen University (1) · Taichung Veterans General Hospital (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1)
China (12) · Taiwan (1)
Caicun Zhou, MD, PHD (2) · Kai Wang, PhD (1) · Ling Xu, MD & PhD (1) · Lizhi Liu, M.D. (1) · Ming Zeng, MD PhD (1) · Shenglin Ma, MD (1) · Yongchang Zhang (1) · Yongchang Zhang, MD (1) · Yuankai Shi, MD (1)
PMID 22452895, PMID 22452896, PMID 23816960, PMID 23816963, PMID 24439929, PMID 26156651, PMID 27577069, PMID 31333456, PMID 35248866